The Angiogenesis Foundation
| Company type | Cambridge, MA |
|---|---|
| Founder | William W. Li, MD |
| Headquarters | Cambridge, MA, U.S. |
| Revenue | 1,772,286 United States dollar (2017)  |
| Website | angio.org |
The Angiogenesis Foundation, is a
501(c)(3) nonprofit organization established in 1994 for the study of angiogenesis. The founders were former students of Dr. Judah Folkman
, a pioneer of angiogenesis research.
The foundation focuses on treatments in the areas of cancer, cardiology, wound healing, dermatology, and ophthalmology.
The foundation developed a therapy for canine cancer, called the Navy Protocol. This treatment works by starving the tumor of its blood supply.[1]
In 1998, the Foundation led the establishment of angiogenic growth factor therapy as the first advanced treatment for diabetic foot ulcers.[citation needed] In 2004, they helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer,[2][failed verification] and later broadening to breast, lung, liver, kidney, and brain cancers.